| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5434171 | CUBIST PHARMS | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
Dec, 2013
(10 years ago) | |
| US5250542 | CUBIST PHARMS | Peripherally selective piperidine carboxylate opioid antagonists |
Mar, 2016
(8 years ago) | |
| US6469030 | CUBIST PHARMS | Methods for the treatment and prevention of ileus |
Nov, 2020
(3 years ago) | |
| US8645160 | CUBIST PHARMS | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
Jun, 2029
(5 years from now) | |
| US8946262 | CUBIST PHARMS | Methods of preventing and treating gastrointestinal dysfunction |
Feb, 2030
(5 years from now) | |
| US8112290 | CUBIST PHARMS | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
Jul, 2030
(6 years from now) | |
Entereg is owned by Cubist Pharms.
Entereg contains Alvimopan.
Entereg has a total of 6 drug patents out of which 3 drug patents have expired.
Expired drug patents of Entereg are:
- US5434171
- US5250542
- US6469030
Entereg was authorised for market use on 20 May, 2008.
Entereg is available in capsule;oral dosage forms.
Entereg can be used as a method for binding a peripheral opioid receptor, a method of treating or preventing ileus, a method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery, treating a subject undergoing abdominal surgery by administering alvimopan to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis, accelerating the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis.
Drug patent challenges can be filed against Entereg from 20 May, 2012.
The generics of Entereg are possible to be released after 31 July, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Oct 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 20, 2013 |
Drugs and Companies using ALVIMOPAN ingredient
NCE-1 date: 20 May, 2012
Market Authorisation Date: 20 May, 2008
Treatment: A method for binding a peripheral opioid receptor; A method of treating or preventing ileus; Treating a subject undergoing abdominal surgery by administering alvimopan to accelerate the time to upper ...
Dosage: CAPSULE;ORAL
ENTEREG family patents
